Web Exclusives

Approximately 40% of children with acute lymphoblastic leukemia (ALL) fail to take 6-mercaptopurine (6-MP) as prescribed, and a sizable majority of parents and children with ALL overreport the intake of a critical drug for maintaining remission, according to a study reported by lead investigator Wendy Landier, PhD, RN, NP, Children’s of Alabama, Birmingham, and colleagues at ASH 2015. The study suggests that electronic reporting using TrackCap, a medication event monitoring system (MEMS), is more reliable than self-reports.

Establishing a Value-Based Paradigm: A Pharmacoeconomic Analysis of Treatment Options

Web Exclusives

Multiple myeloma (MM) is a relatively uncommon malignancy, yet it levies a substantial socioeconomic burden. In 2014, there will be an estimated 24,050 new cases of MM, with 11,090 myeloma-related deaths.

Interpreting Overall Survival Data and Assessing the Value of a Complete Response

Web Exclusives

The value of any intervention for multiple myeloma (MM) must be expressed as an equation: value equals cost plus quality of care. The simplicity of this formula, however, disguises the complexity of cost calculation and quality evaluation.

Considering Duration of Therapy in a Value-Based Plan for Multiple Myeloma

Web Exclusives

Duration of therapy is an important consideration in a valuebased plan for multiple myeloma (MM). This issue has recently received more attention with the increased use of novel targeted agents.

$Optimal Dosing Regimens for Newly Diagnosed and Relapsed/Refractory Multiple Myeloma$

Optimal Dosing Regimens for Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

Web Exclusives

In the treatment of patients with multiple myeloma (MM), dosing is an important but often overlooked ontributor to the value of care.

Cost-Effective Use of Imaging Modalities for Diagnosis and Monitoring in Multiple Myeloma

Web Exclusives

Identification, characterization, and management of osteolytic bone lesions are key aspects of care in multiple myeloma.

Overcoming Treatment Challenges in Multiple Myeloma with Alternative Routes of Administration

Web Exclusives

Multiple myeloma (MM) is among the most challenging cancers to treat. Patients diagnosed with this disease are typically older, with a mean age of 62 years for men and 61 years for women.¹ This older, often elderly population is prone to several factors that complicate treatment, including comorbid conditions, decreased physiologic reserve, cognitive and other psychosocial problems, and a greater risk for adverse drug reactions.^2,3

$Novel Strategies for the Management of Relapsed and Refractory Multiple Myeloma$

Novel Strategies for the Management of Relapsed and Refractory Multiple Myeloma

Web Exclusives

Recent clinical evidence supports new strategies for the management of patients with relapsed and refractory multiple myeloma (MM), including the use of both approved and investigational targeted agents, new dosing regimens for established therapies, and refined, individualized sequencing plans. These approaches have the potential to benefit both clinicians and payers who strive to enhance outcomes and provide value-based care in the relapsed/refractory setting.

Interpreting Progression-Free Survival Data for Value-Based Myeloma Care

Web Exclusives

To determine the value of treatments for multiple myeloma (MM), healthcare professionals must evaluate supporting clinical evidence.

Enhancing Value-Based Decision-Making With Cytogenetic Findings

Web Exclusives

Over the past 20 years, research in multiple myeloma (MM) has delineated the molecular and genetic mechanisms of the disease.

Web Exclusives

Page 2 of 4